Clinical trial
A Randomized, Double Blinded, Sham Controlled Clinical Study to Evaluate the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, for the Acute Treatment of Migraine
NCT03361423 is registered in ClinicalTrials.gov with Theranica as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double Blinded, Sham Controlled Clinical Study to Evaluate the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, for the Acute Treatment of Migraine
- Lead sponsor
- Theranica
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- December 17, 2017
- Completion date
- December 25, 2018
- Enrollment
- 296 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.